Citrus limonin lacks the antichemotherapeutic effect in human models of breast cancer.

Q Agricultural and Biological Sciences

Journal of Nutrigenetics and Nutrigenomics Pub Date : 2012-01-01 Epub Date: 2012-08-17 DOI:10.1159/000336921

Siva Somasundaram, Janet Price, Karen Pearce, Ryan Shuck, G K Jayaprakasha, Bhimanagouda Patil

{"title":"Citrus limonin lacks the antichemotherapeutic effect in human models of breast cancer.","authors":"Siva Somasundaram, Janet Price, Karen Pearce, Ryan Shuck, G K Jayaprakasha, Bhimanagouda Patil","doi":"10.1159/000336921","DOIUrl":null,"url":null,"abstract":"Background/aims: Chemicals that interfere with reactive oxygen species metabolism can act as potential candidates for the treatment of cancer. Some of the glucosides of citrus limonin inhibit the endogenously generated reactive oxygen species. The aim is to study the interactions of limonin with chemotherapy.Methods: Breast cancer cell lines MCF-7 (p53 wild type) and MDA-MB-231 (p53 mutant) as well as the nontumorigenic epithelial cell line MCF-10 were used to screen the effect of limonin at 1-, 5- and 10-µM concentrations with camptothecin for apoptosis and NFĸB, p38 and ERK-MAPK signaling kinase assays. The effect of cyclophosphamide and limonin on MDA MB 231 xenografts was also studied.Results: Our results indicate that limonin did not inhibit camptothecin-induced apoptosis in human breast cancer cells in vitro through noninterference of camptothecin-induced phosphorylation of p38 MAPK and ERK-MAPK. Using an in vivo model of human breast cancer, limonin in combination with cyclophosphamide was not found to inhibit the cyclophosphamide-induced tumor regression through a reduced mitotic index of tumor xenograft cells when compared to treatment with cyclophosphamide alone.Conclusion: Both in vitro and in vivo results suggest that limonin could be beneficial for breast cancer patients undergoing chemotherapy.","PeriodicalId":54779,"journal":{"name":"Journal of Nutrigenetics and Nutrigenomics","volume":" ","pages":"106-14"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000336921","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nutrigenetics and Nutrigenomics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000336921","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2012/8/17 0:00:00","PubModel":"Epub","JCR":"Q","JCRName":"Agricultural and Biological Sciences","Score":null,"Total":0}

引用次数: 9

Abstract

Background/aims: Chemicals that interfere with reactive oxygen species metabolism can act as potential candidates for the treatment of cancer. Some of the glucosides of citrus limonin inhibit the endogenously generated reactive oxygen species. The aim is to study the interactions of limonin with chemotherapy.

Methods: Breast cancer cell lines MCF-7 (p53 wild type) and MDA-MB-231 (p53 mutant) as well as the nontumorigenic epithelial cell line MCF-10 were used to screen the effect of limonin at 1-, 5- and 10-µM concentrations with camptothecin for apoptosis and NFĸB, p38 and ERK-MAPK signaling kinase assays. The effect of cyclophosphamide and limonin on MDA MB 231 xenografts was also studied.

Results: Our results indicate that limonin did not inhibit camptothecin-induced apoptosis in human breast cancer cells in vitro through noninterference of camptothecin-induced phosphorylation of p38 MAPK and ERK-MAPK. Using an in vivo model of human breast cancer, limonin in combination with cyclophosphamide was not found to inhibit the cyclophosphamide-induced tumor regression through a reduced mitotic index of tumor xenograft cells when compared to treatment with cyclophosphamide alone.

Conclusion: Both in vitro and in vivo results suggest that limonin could be beneficial for breast cancer patients undergoing chemotherapy.

查看原文本刊更多论文

柑橘柠檬苦素在人类乳腺癌模型中缺乏抗化疗作用。

背景/目的:干扰活性氧代谢的化学物质可以作为治疗癌症的潜在候选者。柑桔柠檬苦素中的一些糖苷抑制内源性活性氧的产生。目的是研究柠檬苦素与化疗的相互作用。方法:以乳腺癌细胞系MCF-7 (p53野生型)、MDA-MB-231 (p53突变型)和非致瘤性上皮细胞系MCF-10为实验材料，筛选1、5、10µM浓度的柠檬酸素与喜树碱对细胞凋亡的影响，并检测NFĸB、p38和ERK-MAPK信号激酶。研究了环磷酰胺和柠檬苦素对MDA - MB - 231异种移植物的影响。结果:我们的研究结果表明，柠檬苦素通过不干扰喜树碱诱导的p38 MAPK和ERK-MAPK磷酸化，对喜树碱诱导的体外人乳腺癌细胞凋亡没有抑制作用。在人乳腺癌的体内模型中，与单用环磷酰胺相比，柠檬茅素联合环磷酰胺并没有通过降低肿瘤异种移植细胞的有丝分裂指数来抑制环磷酰胺诱导的肿瘤消退。结论:体外和体内实验结果均表明柠檬苦素对乳腺癌化疗患者有益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Nutrigenetics and Nutrigenomics GENETICS & HEREDITY-NUTRITION & DIETETICS

CiteScore

1.86

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： The emerging field of nutrigenetics and nutrigenomics is rapidly gaining importance, and this new international journal has been established to meet the needs of the investigators for a high-quality platform for their research. Endorsed by the recently founded "International Society of Nutrigenetics/Nutrigenomics", the ‘Journal of Nutrigenetics and Nutrigenomics’ welcomes contributions not only investigating the role of genetic variation in response to diet and that of nutrients in the regulation of gene expression, but is also open for articles covering all aspects of gene-environment interactions in the determination of health and disease.